WTO versus Humankind?
Bharat Jhunjhunwala
In the main two vaccines are available to us today Covishield developed by AstraZeneca and produced under its license by Serum Institute of India; and Covaxin developed by Bharat Biotech. Serum Institute has to pay one-half of the sale price to AstraZeneca as royalty; or it has to pay Rs 75 as royalty if it sells Covishield to the Central Government at Rs 150. Serum Institute says that it is not economic for it to produce Covishield in the balance Rs 75. For this reason, they have offered to sell Covishield only at Rs 300 to the States and at a higher price to the private buyers. In this way the States will be buying Covishield at Rs 300 and subsidizing the purchase by Center at Rs 150. The Center should act as father of the States. Instead it is acting as their opponent. This is a minor problem, however. Serum Institute is having to pay this huge amount of royalty because we have accepted Product Patents under the World Trade Organization
A Comprehensive Study Exploring Patent Medicine Market | Key Players Novartis, Otsuka Pharmaceutical, Pfizer, Merck
iCrowd Newswire
06 May 2021, 20:08 GMT+10
A new business intelligence report released by HTF MI with title Global Patent Medicine Market Growth (Status and Outlook) 2021-2026 is designed covering micro level of analysis by manufacturers and key business segments. The Global Patent Medicine Market survey analysis offers energetic visions to conclude and study market size, market hopes, and competitive surroundings. The research is derived through primary and secondary statistics sources and it comprises both qualitative and quantitative detailing. Some of the key players profiled in the study are Pfizer Inc., Otsuka Pharmaceutical, Merck, Novartis, Sanofi-Aventis, Bristol-Myers Squibb Co. & GSK.